HER2
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
HER2
Jul 25, 2024, 07:47 |
Insight
HER2-targeted therapies beyond breast cancer
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jul 22, 2024, 23:09 |
Blog
Aleix Prat: TNBC-DX - new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC)
Aleix Prat, Director of Cancer Institute and Blood Disorders at Clinical Hospital of Barcelona, shared…
Jul 16, 2024, 13:20 |
Blog
Mya Tran: Another year of many developments in precision medicine
Mya Tran, Thoracic Clinical Pharmacist, PharmD, BCOP, at Indiana University Health - Simon Comprehensive Cancer Center,…
Jun 29, 2024, 09:05 |
Blog
Erika Hamilton: Always worth major celebration when we see survival improve by 10 months in metastatic cancer
Erika Hamilton shared a post by Healthbook on LinkedIn, adding: "Always worth major celebration when we…
Jun 27, 2024, 12:32 |
Insight
Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525
Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn: “We are…
Jun 26, 2024, 03:18 |
Insight
Paolo Tarantino: The 5 S rules help memorizing a simple framework to manage ILD
Paolo Tarantino shared on LinkedIn: “T-DXd is rapidly expanding in indications, from HER2+, to HER2-low, and…
Jun 25, 2024, 16:01 |
Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X: . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
Jun 25, 2024, 07:47 |
Blog
Mark Lewis: It is UNACCEPTABLE to treat mCRC without knowing these biomarker
Mark Lewis shared a post by FDA Oncology on X, adding the following: . “We…
Jun 23, 2024, 10:53 |
Blog
Breaking Science in Breast Cancer with Hope Rugo - ESMO
ESMO shared a post on LinkedIn: "For ESMO members: Breaking Science in Breast Cancer. Hope Rugo…
Jun 20, 2024, 16:00 |
Insight
Andrew Parsonson: Median pooled OS over 5 years for MBC on first line ET and CDK4/6
Andrew Parsonson, Medical Oncologist at Nepean Blue Mountains Local Health District (NBMLHD), shared a post…
May 29, 2024, 08:20 |
Blog
Paolo Tarantino: In this work by the AZ translational team, QCS proved superior to manual IHC in predicting the activity of T-DXd
Paolo Tarantino shared a post on X: "In the ph1 trial of T-DXd in HER2-low MBC,…
May 29, 2024, 03:24 |
Insight
Ibrahim Sahin: Just had chance to read the full article on ‘HER2 amplified’ CRC
Ibrahim Sahin, Assistant Professor at UPMC Hillman Cancer Center, shared a post on X: “Just…
May 26, 2024, 06:49 |
Societies
Paolo Tarantino: Less than a week to what promises to be a terrific ASCO24
Paolo Tarantino recently shared a post on X: "Less than a week to what promises…
May 25, 2024, 11:59 |
Blog
Vivek Subbiah: ASCO 24 time to learn the latest and greatest in Tissue Agnostic Precision Medicine
Vivek Subbiah shared on X: “It's ASCO 24 time Mark your calendars to learn the latest…
May 24, 2024, 00:58 |
Blog
Francisco J. Esteva on the DESTINY-Breast06 trial
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared…
May 21, 2024, 07:42 |
Blog
Chiara Molinelli: Check out our poster at ESMOBreast24
Chiara Molinelli, Oncologist and Medical Research Fellow at Ospedale San Martino Genova, shared a post…
May 19, 2024, 10:55 |
Insight
Dhruba Deb: The 8 SCLC projects Lung Cancer Research Foundation recently funded
Dhruba Deb, Senior Director of Research and Administration at Lung Cancer Research Foundation, shared on…
May 17, 2024, 12:54 |
Insight
Piotr Wysocki: Anti-HER2 treatment in patients with advanced biliary cancer
Piotr Wysocki recently posted on LinkedIn: "The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is…
May 16, 2024, 09:09 |
Blog
Kohei Shitara: Happy to report biomarkers in DESTINIY GC01 at Nature Medicine
Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan shared a post on X:…
May 11, 2024, 11:23 |
Insight
Matt Sagan: Moving from HER2+ to HER2-low to HER2- ultralow
Matt Sagan, Co-Founder and CEO of FiBioMed, shared a post by Paolo Tarantino on X,…
May 2, 2024, 15:20 |
Blog
Paolo Tarantino: Impressive to think at the journey of ADCs over the last five years
Paolo Tarantino shared on LinkedIn: "Impressive to think at the journey of ADCs over the last…
May 1, 2024, 12:05 |
Blog
Paolo Tarantino: Refresher for the current and upcoming definitions of HER2 in breast oncology
Paolo Tarantino shared on X/Twitter: "Refresher for the current and upcoming definitions of HER2 in breast…
Apr 28, 2024, 05:14 |
Insight
Aleix Prat: Our new article about attitudes towards HER2DX in Spain
Aleix Prat, Director of the Cancer Institute at Hospital Clinic of Barcelona, shared on X/Twitter:…
Apr 26, 2024, 17:44 |
Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 21, 2024, 11:35 |
Insight
Samuel Kareff: Our pan-tumor analysis on the not-so-elusive HRAS mutation in solid tumors
Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, shared…
Apr 20, 2024, 20:17 |
Insight
Paolo Tarantino: Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer
Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X: "Tumor-infiltrating lymphocytes (TILs): not…
Apr 12, 2024, 05:16 |
Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Apr 11, 2024, 08:13 |
Drugs
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…
Apr 8, 2024, 15:41 |
Drugs
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…
Apr 8, 2024, 03:54 |
Drugs
Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
Mar 22, 2024, 06:12 |
Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
Mar 21, 2024, 10:54 |
Insight
The Swedish SCAN-B cohort, the HER2DX risk-score was found significantly associated with OS after adjustment for clinical variables and treatment regimen - ESMO Open
ESMO Open posted on X: "Hot off the press: among 757 patients with early HER2+ breast…
Mar 18, 2024, 19:11 |
Blog
Fredrick Chite Asirwa: International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently
Fredrick Chite Asirwa, CEO/Executive Director of International Cancer Institute, posted on LinkedIn: "To contribute to…
Mar 16, 2024, 20:07 |
Insight
Erman Akkus: HER2 and mCRC on Journal of Clinical Oncology
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "HER2 and mCRC on…
Mar 12, 2024, 21:01 |
Blog
Rebecca Shatsky: Got to meet the fantastic Sumanta Pal in person finally, as well as his incredible fellow
Rebecca Shatsky and Sumanta Pal, Professor and Vice Chair of Academic Affairs, City of Hope…
Feb 18, 2024, 13:29 |
Blog
Aydah AlAwadhi: Delighted to have been part of the 12th Annual Beirut Breast Cancer Conference
Aydah AlAwadhi, Consultant Medical Oncologist at Abu Dhabi Health Services Company, recently posted on LinkedIn:…
Feb 11, 2024, 15:45 |
Blog
Paolo Tarantino: In a large RW cohort we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: “In…
Feb 8, 2024, 17:54 |
Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Feb 1, 2024, 15:19 |
Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 14, 2024, 15:07 |
Insight
Francisco J. Esteva: The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital,…
Jan 10, 2024, 18:21 |
Blog
Top Precision Oncology articles of 2023 by Vivek Subbiah
Vivek Subbiah shared on X/Twitter: "By popular demand delighted to share the 'Top Precision Oncology…
Dec 14, 2023, 16:23 |
Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Jul 27, 2023, 07:14 |
Blog
DAISY Such a key publication in our growing understanding of T-DXd - Stephanie Graff
DAISY Such a key publication in our growing understanding of T-DXd, particularly across the spectrum…
Jul 14, 2023, 02:41 |
Insight
HER2 protein and mRNA expression and amplifications among 5,305 diverse cancers is HIGHLY VARIABLE - Jacob J. Adashek, DO
OUT TODAY in JCO Precision Oncology with Medical College, Dr. Razelle Kurzrock! HER2 protein and…
Jul 10, 2023, 04:23 |
Insight
Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer - Stephanie Graff, MD, FACP
Now in CBC journal : Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast…
Jun 14, 2023, 18:35 |
Drugs
Can we improve the delivery of eribulin by linking it to a HER2 mAb?
In a post by Paolo Tarantino on Twitter, it says, "Can we improve the delivery…
Jun 6, 2023, 19:11 |
Opinion
HER2-low is a dynamic, rather than static definition! - Paolo Tarantino
Retrospective HER2-low analysis of 512 patients with TNBC presented by Yale Bar. confirms high discordance…
All:
47
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube